Robert Charles Breedlove net worth and biography

Robert Breedlove Biography and Net Worth

Robert Breedlove is the former Senior Manager at van den Boom & Associates, an accounting and finance consulting firm. In this role, he oversaw the development of several finance and accounting departments at clinical and commercial stage life sciences companies. Previously, Mr. Breedlove served as the Manager of Financial Reporting and Compliance at Neogenomics and prior to that held numerous roles of increasing responsibility at Ernst & Young.

Mr. Breedlove is a Certified Public Account and earned his B.A. and M.A. in accountancy from the University of San Diego.

What is Robert Charles Breedlove's net worth?: The estimated net worth of Robert Charles Breedlove is at least $550.40 thousand as of November 3rd, 2025. Breedlove owns 47,407 shares of Phathom Pharmaceuticals stock worth more than $550,395 as of February 24th. This net worth approximation does not reflect any other assets that Breedlove may own. Learn More about Robert Charles Breedlove's net worth.
How do I contact Robert Charles Breedlove?: The corporate mailing address for Breedlove and other Phathom Pharmaceuticals executives is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. Phathom Pharmaceuticals can also be reached via phone at 877-742-8466 and via email at [email protected]. Learn More on Robert Charles Breedlove's contact information.
Has Robert Charles Breedlove been buying or selling shares of Phathom Pharmaceuticals?: Robert Charles Breedlove has not been actively trading shares of Phathom Pharmaceuticals during the past quarter. Most recently, Robert Charles Breedlove sold 524 shares of the business's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $13.51, for a transaction totalling $7,079.24. Following the completion of the sale, the insider now directly owns 47,407 shares of the company's stock, valued at $640,468.57. Learn More on Robert Charles Breedlove's trading history.
Who are Phathom Pharmaceuticals' active insiders?: Phathom Pharmaceuticals' insider roster includes Robert Breedlove (Insider), Terrie Curran (Insider), Molly Henderson (CFO), Frank Karbe (Director), Azmi Nabulsi (COO), Asit Parikh (Director), David Socks (Director), and James Topper (Director). Learn More on Phathom Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Phathom Pharmaceuticals?: During the last year, Phathom Pharmaceuticals insiders bought shares 2 times. They purchased a total of 8,780 shares worth more than $27,590.80. During the last year, insiders at the sold shares 4 times. They sold a total of 6,355 shares worth more than $43,532.75. The most recent insider tranaction occured on November, 3rd when insider Robert Charles Breedlove sold 524 shares worth more than $7,079.24. Insiders at Phathom Pharmaceuticals own 24.1% of the company. Learn More about insider trades at Phathom Pharmaceuticals.
Information on this page was last updated on 11/3/2025.

Robert Charles Breedlove Insider Trading History at Phathom Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/3/2025	Sell	524	$13.51	$7,079.24	47,407
9/5/2025	Sell	461	$12.09	$5,573.49	47,931
7/16/2025	Sell	1,692	$8.36	$14,145.12	48,392

Robert Charles Breedlove Buying and Selling Activity at Phathom Pharmaceuticals

Phathom Pharmaceuticals Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $11.61

$11.19

$11.69

50 Day Range

MA: $14.59

$11.37

$18.16

2 Week Range

Now: $11.61

$2.21

$18.31

Volume

804,879 shs

Average Volume

1,157,794 shs

Market Capitalization

$829.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51